55 results about "Beta-cell Function" patented technology

The invention relates to a probiotic composition, and discloses a probiotic composition beneficial for a glycolipid metabolic function and a preparation and application of the composition. The probiotic composition comprises some of the following nine probiotics: bifidobacterium longum, bifidobacterium breve, lactobacillus gasseri, lactobacillus rhamnosus, lactobacillus salivarius, lactobacillus crispatus, lactobacillus plantarum, lactobacillus fermentum and lactobacillus casei. Different strains in the probiotic composition cooperate with each other, so that the probiotic composition has thefunction of adjusting glycolipid metabolism, and has certain effect on serum total cholesterol, triglycerides, insulin beta-cell functions and diabetes mellitus improvement.

The invention relates to new methods and compositions for treating diabetics, pre-diabetics, and patients at risk of becoming diabetic or with impaired glucose tolerance. The invention, in one embodiment, involves activating insulin receptor substrate-2 to protect against loss of beta cell mass, protect against loss of beta cell function, rejuvenate beta cells mass, rejuvenate beta cell function or any combination thereof, thereby stimulate insulin production using an effective amount of LySB3,GluB29 insulin to patients in need of this treatment.

The invention relates to the prediction of sulfonylureas drug effect by measuring polymorphism site genetype of sulfonylureas recepted gene, and the method. It predicts the effect of sulfonylureas drug in reducing blood sugar, improving and restoring Langer-hans' insula beta cell function and / or intensifying insulin sensitive function by measuring polymorphism site genetype of sulfonylureas recepted gene; and predicts the effect of sulfonylureas drug in reducing blood sugar, improving and restoring Langer-hans' insula beta cell function and / or intensifying insulin sensitive function by making use of polymorphism parting oligonucleotide to detect polymorphism site genetype of sulfonylureas recepted gene in biological sample. The invention can indicate doctor to choose medicine according to individual gentic difference, increase the effective rate of clinical medicine treating and safty of clinical midicine usage, reduce toxic and side effect of medicine and economical load, and reduce diabetes complication generation.

The invention relates to a health-care product assisted to reduce blood glucose. The health-care product is prepared from the following raw components in parts by weight: 3-8 parts of jerusalem artichoke, 5-10 parts of portulaca oleracea, 3-8 parts of pseudo-ginseng, 1-3 parts of astragalus membranaceus, 2-3 parts of bitter gourd, 1-3 parts of trichosanthes kirilowi root, 2-5 parts of rhizoma anemarrhenae, 2-5 parts of rehmannia, and 2-5 parts of dendrobe. The health-care product can be prepared into capsules or troches through a conventional preparation process. The health-care product disclosed by the invention is enriched in a variety of plant saponins, polysaccharides, protein, fat, saccharides, mineral substances and vitamins; nutritional components are comprehensive and balanced; physiological functions of patients suffering from diabetes can be improved radically; islet beta cell functions are recovered; the symptoms of patients suffering from diabetes, such as lung deficiency, spleen deficiency and kidney deficiency, can be eliminated; diabetic complications are prevented and lightened; blood glucose is stably reduced; therefore, the purposes of treating both symptoms and root causes are achieved; and the health-care product disclosed by the invention is convenient to eat and easy to absorb by human bodies, and is applied to crowds suffering from diabetes.

The invention belongs to the field of gene engineering, and in particular relates to application of Lincpint in preparation of T2DM prediction and targeted treatment drugs, down-regulation of the Lincpint in T2DM mice is relate to function injuries of pancreatic beta cells, the Lincpint of a low expression level may participate the pathogenesis of the T2DM, and by change of the expression of the Lincpint, the apoptosis of the pancreatic beta cells and synthesis and secretion of insulin can be influenced.

The invention belongs to the traditional Chinese medicine field, and concretely discloses a traditional Chinese medicinal compound preparation for treating the type 2 diabetes. The traditional Chinese medicinal compound preparation for treating the type 2 diabetes is prepared through adopting Radix Scutellariae, Rhizoma Coptidis and Radix Puerariae as primary medicines and mixing with auxiliary medicines. The invention also discloses a preparation method of the traditional Chinese medicinal compound preparation for treating the type 2 diabetes. Experiments show that the traditional Chinese medicinal preparation can adjust the glycometabolism of patients suffering from the type 2 diabetes, and can also improve the islet beta cell functions of the patients. The preparation can well treat the type 2 diabetes, and has the advantages of small dosage, appropriate price, safety and effectiveness after long-term taking, and good patient evaluation.

The invention relates to a blood-sugar reducing tea and a preparation method thereof. The blood-sugar reducing tea is prepared by taking guava leaves, flos notoginseng, fructus momordicae and jasmine flowers as the materials through the steps of selecting the materials and removing impurities as well as rotten and deteriorated materials, then drying under 50-85 DEG C, cracking, and screening through vibrating screen; and then taking 20-60 meshes of materials, mixing, sterilizing and packaging the materials according to proportions. The blood-sugar reducing tea and the preparation method thereof have the advantages of unique composing prescription, confirmed curative effect, convenient use, economy, safety and no side effect, has the effects of clearing heat and promoting the secretion of saliva or body fluid, reducing sugar and removing fat, dispersing stagnation and dredging collaterals, and is applicable to patients with abnormal sugar tolerance and diabetics to use. Experiment research shows that the blood-sugar reducing tea and the preparation method thereof have the effects of reducing blood sugar and lightening insulin resistance, increasing insulin sensitivity, protecting Beta cell functions, and reducing serum total cholesterol and serum triglyceride without toxic side effects.

Since glucagon-like peptide-1 (GLP-1) is the most potent insulinotropic hormone known and has been shown to stimulate insulin secretion strongly in patients with type II diabetes, this invention uses GLP-1 or its biologically active analogues in β-cell stimulatory tests in order to test β-cell function in a simple way. The test provides information about insulin secretory capacity, is easy and reproducible and has insignificant side effects.

Disclosed are methods for improvement of beta cell function in a subject using an anti-IL-1β antibody or fragment thereof.

The invention relates to a medicine combination for treating the impaired glucose tolerance and the preparing method thereof. The medicine combination is mainly composed of balsam pear, mulberry leaf, sanchi, glossy privet fruit, fiveleaf gynostemma herb, chromium picolinate, and zinc gluconate. It is a preparation produced by pharmacological acceptable carrier or excipient, containing capsule, granule, tablet, soft capsule, dropping pill and etc, which is suitable for the patent with impaired glucose tolerance and forepart diabetes. The research indicates that the invention can reduce the blood sugar, decline the insulin resistance, enhance the insulin sensitivity, protect the beta cell function, reduce the serum total cholesterol and serum triglyceride without side and poisonous effects.

The invention relates to a preparation method of diabetes vaccine based on a (M)T-DC technology. The preparation method selects a specific single-epitope multiple antigen peptide in-vitro sensitization dendritic cell to obtain an auto-dendritic cell preparation serving as venous re-transfusion diabetes vaccine. According to the preparation method, the (M)T-DC technology is adopted to interfere andremove a blood vessel endothelium infectious factor, the vaccine can deeply enter a lesion local part in a targeting manner, the blood vessel endothelium is restored by combining multi-direction differentiation potential mesenchymal stem cell therapy of a corresponding treatment course, cicatrix is dissolved, the pancreatic tissue is restored, the pancreatic immunity system is restored, and an insulin beta cell function is recovered, so that the insulin can secrete normally, thereby achieving a treatment purpose.

The invention discloses new long-acting GLP-1 (glucagonlike peptide-1) compounds, a medicine composition containing the compounds, wherein the compound is used for (1) treatments of hyperglycemia, type 2 diabetes, type 1 diabetes, impaired glucose tolerance, obesity, hypertension, X syndrome, dyslipidemia, cognitive disorder, myocardial infarction, coronary heart disease and other vascular diseases, apoplexy, dyspepsia and gastric ulcer, (2) or reducing food intake and beta-cell apoptosis, enhancing beta-cell function and beta-cell quantity , and or, recovering the glucose sensitivity of beta-cell.

The invention belongs to the field of medicines. Danshinolic acid B has functions of inhibition of islet amyloid polypeptide aggregation and treatment of diabetes. The in-vivo islet amyloid polypeptide aggregation can destroy a beta-cell membrane structure and a normal form function of mitochondria to cause beta-cell apoptosis and damage a beta-cell function, thereby being taken as an important nosogenesis of type-2 diabetes. By danshinolic acid B, the aggregation of the islet amyloid polypeptide can be inhibited, and the process of damaging the beta-cell membrane structure and the normal form function of mitochondria during aggregation is changed over to protect the beta-cells, so that danshinolic acid B can be used for preventing and treating the diabetes.

A new method for improvement of functions of diabetes islet beta cells is provided by combination of human umbilical cord mesenchymal stem cells and incretin, and the new method is as follows: on the basis of application of the human umbilical cord mesenchymal stem cells for treatment of type-1 and type-2 diabetes, the incretin (GLP-1 (glucagon-like peptide-1) receptor agonist and DPP-4 (dipeptidyl peptidase-4) inhibitor) is combined. The new method can promote islet beta cell proliferation and regeneration, improve the functions of the islet beta cells, reduce blood sugar and glycated hemoglobin, reduce islet alpha hyperplasia and inhibit glucagon secretion, and thus playing a synergy effect.

A pharmaceutical composition for treatment for of r afflicted or in risk of becoming of impaired glucose tolerance (IGT) and / or type-2 it comprising an effective amount of relaxin for protecting beta-cells and beta-cell function against the effects of high blood glucose (glucotoxicity). Treatment of persons of disglycaemias, and protection of beta cells of the islets of Langerhans and beta-cell function in patients having type-2 diabetes, is diclosed.

The invention relates to the field of treatment of functions of islet cells and particularly relates to Quzhou fructus aurantii, a Quzhou fructus aurantii extract and application of a medicine composition containing Quzhou fructus aurantii or Quzhou fructus aurantii extract to protection of islet cells, recovery of the functions of the islet cells, acceleration of insulin secretion or increase ofthe number of the islet cells. The invention creatively develops new medicinal application of Quzhou fructus aurantii and also develops a new application field. The Quzhou fructus aurantii has the effects of protecting the islet cells, accelerating the insulin secretion, recovering the depleted islet cells and increasing the number of the islet cells, has strong pharmacological effects, and is safe and non-toxic; the product is safe, is rich and cheap in raw material resources, free of toxic and side effects, simple in preparation process route, low in production cost and convenient to use, can be prepared into the conventional preparations such as oral preparations and tablets and the like, and is used as an islet cell protection agent which is extremely promising and has good developmentvalue.

The present invention provides compositions for use in the treatment of long- established type 1 diabetes (TID) using peptides and analogs of heat shock protein 60 (Hsp60). The invention is exemplified using DiaPep277, a peptide analog of human Hsp60, which is shown to induce increase in plasma C-peptide and regeneration of islet beta cells. The invention further relates to regimens useful for treatment of long established TID in patients having no demonstrable islet beta cell-function.

Compositions and methods for production of beta islet cells exhibiting superior endocrine like functions are disclosed.

The invention discloses application of mTORC1 in medicines for regulating and controlling the functions and conversion of pancreatic beta cells; and the functions of pancreatic beta cells are improvedby regulating the activity or regulation bypass of mTORC1 passages and / or the pancreatic non-beta cells are converted into new pancreatic beta cells. The conversion is gene recording without a differentiation process. The invention discloses that the mTORC1 passages are of an important role in identity maintenance of beta cells. The specific Raptor knockout of the beta cells can cause functionaldisorders and cell immaturity of the beta cells as well as hyperglycemia since metabolic requirements cannot be met, and simultaneously causes expression increase of MafB, so that transdifferentiationis caused. The activity of the mTORC1 passages is adjusted, or regulation bypasses of the mTORC1 passages can serve as a new target spot for beta cell therapy, and the functions of the beta cells areimproved, or new beta cells are generated by non-beta cells.

The invention discloses application of a PKC enzyme inhibitor in preparing a drug for improving and protecting islet beta cell functions. Through a series of experiments, it is verified that the PKC enzyme inhibitor has a good inhibitory effect on THAP-induced islet beta cell apoptosis, can significantly inhibit the expression of TXNIP and can effectively inhibit the expression of mRNA and proteinwhich are related to endoplasmic reticulum stress. The PKC enzyme inhibitor can provide a good candidate drug for clinical treatment of diabetes caused by the apoptosis and decrease of islet beta cells, and has a very good application prospect.

The invention discloses a traditional Chinese medicine formula for treating type 2 diabetes melitus and a preparation method of dissolved medicine thereof. According to the formula,effective constituents of monarch medicine of ginseng and inonotus obliquus reduce blood glucose and recovers the body function of a patient,then minister medicine is combined to relieve diabetes mellitus symptoms and improve the immunity and cell activity of the human body,so that the patient can recover a beta cell function,and diabetes is radically cured; according to the preparation method,extraction is carriedout in two kinds of methods on the physical properties of the effective constituents in the inonotus obliquus,and the ginseng is prepared into powder to be mixed with the dissolved medicine for improving the utilization rate of the precious medicinal materials.

The invention belongs to the field of bio-pharmacy, and particularly relates to a recombinant GLP-1 analogue Fc fusion protein optimized gene (rGLP-1-Fc for short) and an application thereof. The human GLP-1 analogue Fc fusion gene is optimized, introduced into a plasmid and transfected into CHOK1SV GS-KO cells, and after screening, a positive CHOK1SV GS-KO cell line expressing GLP-1 analog Fc fusion protein stably and efficiently is obtained. The constructed optimized gene has the advantages that the secretion and expression amount in positive cell strains is increased significantly, the secreted fusion protein has higher biological activity and can directly act on a GLP-1 receptor, and affinity is higher; blood sugar and glycosylated hemoglobin can be reduced rapidly, efficiently and permanently; the optimized gene has functions of improving islet beta cell function, reducing blood fat, reducing weight, delaying gastric emptying, increasing satiety and the like.

The invention relates to a gene engineering stem cell which is prepared by the following steps: transforming betatrophin gene cDNA (complementary deoxyribonucleic acid) plasmid into mesenchymal stem cell by using gland related virus AAV6 as a vector for carrying, and overexpressing the betatrophin molecule to obtain the betatrophin gene engineering stem cell. The gene engineering stem cell can be input into the human body via the veins to treat Type 2 diabetes; and the gene engineering stem cell can control to stimulate the proliferation of the endogenous pancreatic island beta cell to restore the failed beta cell function, and can also display the immunoregulation and insulin resistance improvement functions of the paracrine / autocrine of the stem cell, thereby basically improving the prognoses of patients with Type 2 diabetes.

The invention discloses application of hydroxy-alpha-sanshool in preparation of a medicine for regulating blood glucose. Hydroxy-alpha-sanshool and pharmaceutically acceptable accessories or carriersare prepared into an oral preparation, which can be used as a medicine for regulating blood glucose; the medicine has the effects of improving the islet beta-cell function of a person or animal and reducing the blood glucose of the person or animal; the mass percentage content of the hydroxy-alpha-sanshool in the medicine for regulating blood glucose can be 0.1% to 100%; the technical personnel inthe field can easily determine the administration dosage according to an actual situation; due to oral administration of the hydroxy-alpha-sanshool in the invention, the blood glucose of a metabolicsyndrome model mouse can be decreased significantly; simultaneously, the HOMA-beta index is obviously increased; and it shows that the hydroxy-alpha-sanshool can be used for treating diabetes.

The invention belongs to the technical field of pharmacy, and relates to an application of a dendrobium nobile water extract in treating type 2 diabetes mellitus, in particular to regulation of insulin resistance and triglyceride synthesis of a dry dendrobium water extract and a fresh dendrobium water extract in a high-sugar state. Experimental results prove that the dendrobium nobile water extract prepared by the invention can obviously inhibit the expression level of mRNA of fatty acid binding protein, improve the peripheral insulin resistance, protect the pancreatic beta cell function, increase insulin sensitivity, obviously inhibit the expression level of diacylglycerol acyltransferase mRNA, reduce the TG biosynthesis, improve the sensitivity of the body to insulin and leptin, increasethe mRNA expression level of sterol regulatory element-binding protein 1, and effectively regulate the triglyceride biosynthesis so as to achieve inhibition of type 2 diabetes mellitus from multipleaspects. Therefore, the dendrobium nobile water extract disclosed by the invention can be used for treating type 2 diabetes mellitus and has a good development prospect in the aspect of treating type2 diabetes mellitus.

The invention discloses a traditional Chinese medicine composition which contains dried ginger, radix scutellariae, rhizoma coptidis, radix codonopsis, poria cocos, rhizoma atractylodis, cinnamon, radix paeoniae rubra, radix puerariae, radix et rhizoma rhei, corn stigma, gypsum, red yeast rice and stevia rebaudiana. The invention also discloses an application of the traditional Chinese medicine composition in preparation of medicines for preventing and / or treating diabetes mellitus. Monitoring of oral glucose tolerance, glycosylated hemoglobin, insulin resistance levels and pancreatic beta cell functions of diabetic patients proves that the traditional Chinese medicine composition has the treatment effects of reducing the blood sugar of the diabetic patients, improving the pancreatic function of the patients and recovering the sensitivity of organisms to insulin.

The invention belongs to the technical field of pharmacy, and relates to application of a fresh dendrobe aqueous extract in preparation of drugs for treating metabolic diseases. The invention particularly relates to adjustment of fatty acid and triglyceride synthesis by a fresh dendrobe aqueous extract. Experimental results prove that the fresh dendrobe aqueous extract prepared by the invention can obviously inhibit the mRNA expression level of sterol regulatory element binding protein 1, diacylglycerol acyltransferase and microsome triacylglycerol transporter, and effectively regulate the biosynthesis of triglyceride; and the fresh dendrobe aqueous extract can obviously inhibit the mRNA expression levels of acetyl-CoA carboxylase, fatty acid synthase and stearoyl-CoA desaturase, and effectively regulate fatty acid synthesis; and the fresh dendrobe aqueous extract can inhibit the mRNA expression level of the FABP4, improve the peripheral insulin resistance, protect pancreatic beta cellfunctions, and improve the sensitivity of insulin, thereby inhibiting the metabolic diseases related to the FABP4; and therefore, the fresh dendrobe aqueous extract prepared by the method can be usedas the drug for treating the metabolic diseases.

The invention relates to diabetes vaccine based on a (M)T-DC (Target-dendritic cell) technology. The vaccine is a dendritic cell preparation obtained by using specific single-epitope multiple antigenpeptides for in-vitro sensitization of dendritic cell and is venous re-transfusion type diabetes vaccine. Removal of a vascular endothelial infection factor is interfered by the (M)T-DC technology, the vaccine can penetrate into the local lesion in a targeted way, corresponding treatment courses of mesenchymal stem cell treatment with multidirectional differentiation potential is also adopted, soas to repair blood vessel endothelium, cicatrix is dissolved, a pancreatic intra-tissue repairing is realized, a pancreatic immune system is repaired and the insulin beta cell function is recovered, so that the treatment aim of enabling insulin secretion to be normal is fulfilled.

The invention discloses application of a serum extracellular vesicle molecular marker hsa-miR-503-5p in preparation of a diagnostic kit for type-2 diabetes, and discloses that the content increase of the serum extracellular vesicle miR-503-5p is closely related to the aggravation of insulin resistance in the morbidity process of the type-2 diabetes and the process of blood glucose homeostasis damaged disease occurrence caused by beta cell function damage. The application provides a powerful molecular biology foundation for diagnosis and typing treatment of type-2 diabetes, and has profound clinical significance and popularization value.

The invention relates to the field of biological medicine, in particular to application of Grb10 as a key negative regulation factor for pancreatic beta cell dysfunction. According to the invention, the physiological function of Grb10 in beta cells is researched, wherein the results show that Grb10 is highly expressed in pancreas and islets of human and mice, and is highly expressed in islets of diabetic mouse models and islets of old people. In addition, the beta cell specific knockout Grb10 increases the beta cell quality and beta cell function of high fat diet (HFD) mice by promoting beta cell maturation and inhibiting beta cell dedifferentiation. According to the invention, the important role of Grb10-mTORC1 interaction in regulating beta cell dedifferentiation is highlighted, and a new insight is provided for a regulating mechanism of beta cell characteristics and functions.